Vaccine developer AstraZeneca acquires Alexion in a controversial move
Investors are uncertain about the acquisition’s merits, due to Alexion’s huge price tag and its relatively meager contribution to AstraZeneca’s future.
British-Swedish vaccine developer AstraZeneca PLC is acquiring the Boston, Massachusetts-based rare diseases specialist Alexion Pharmaceuticals Inc. in a bid to secure a post-coronavirus expansion for the